BioSpace News Archive

ImmunoGen, Inc. announced that on October 31, 2022, the compensation committee of the Company’s Board of Directors approved grants of non-qualified stock option awards to purchase an aggregate of 687,700 shares of its common stock to seventeen new employees under the ImmunoGen, Inc.

Cullinan Oncology, Inc. announced that the compensation committee of the Company’s Board of Directors granted stock option awards to purchase an aggregate of 147,000 shares of its common stock to four employees outside Cullinan Oncology, Inc’s 2021 Stock Option and Incentive Plan.

SeaSpine Holdings Corporation, a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced financial results for the third quarter of 2022.

ChromaCode, Inc., which brings accessible and affordable insights to labs, patients and physicians through its innovative High Definition PCR (HDPCR™) multiplexing solution, announced today that it will present its HDPCR oncology data, studied in collaboration with Thermo Fisher Scientific, on the QuantStudio Absolute Q dPCR* System at the Association for Molecular Pathology (AMP) 2022 Annual Meeting and Expo.

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that it will release its third quarter 2022 financial results and provide a company update after the market closes on Tuesday, Nov. 8, 2022.

Karyopharm Therapeutics Inc. announced that the Company granted stock options to purchase an aggregate of 23,200 shares of Karyopharm’s common stock and an aggregate of 16,000 restricted stock units to seven newly-hired employees.

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced the company has completed the expected tax-free spin-off of its OmniAb antibody discovery business which has become OmniAb, Inc., an independent publicly traded company.

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse disorder (the “Company” or “Anebulo”), today announced the appointment of Dr. Nat Calloway to its Board of Directors.

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today provided a business update and reported its financial results for the third quarter ended September 30, 2022.

Viemed Healthcare, Inc. announced that it has reported its financial results for the three and nine months ended September 30, 2022.